Response to Hjelmesæth et al.
- Victor M. Montori, MD, MSC1,
- Ananda Basu, MD14,
- Patricia J. Erwin, MLS2,
- Sherine E. Gabriel, MD, MSC3 and
- Yogish C. Kudva, MD14
- 1Division of Endocrinology, Diabetes, Metabolism, Nutrition, and Internal Medicine, Mayo Clinic, Rochester, Minnesota
- 2Medical Library, Mayo Clinic, Rochester, Minnesota
- 3Division of Epidemiology, Mayo Clinic, Rochester, Minnesota
- 4Transplant Center, Mayo Clinic, Rochester, Minnesota
We appreciate the comments of Hjelmesæth et al. (1) in this issue of Diabetes Care, who have made important contributions to the field of post-transplantation diabetes (PTD) and thank them for their interest in our work. We echo their remarks about the uncertainty surrounding the true incidence of PTD and agree that prospective studies conducted using sound methods are the best source of reliable estimates of the incidence of PTD. Their work on the impact of glucocorticoids on PTD concurs with the results of …
